Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 201 to 225 of 373

Guidance and quality standards awaiting development
Title	Type
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]	Technology appraisal guidance
Ondansetron for treating alcohol-use disorder [ID6341]	Technology appraisal guidance
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323]	Technology appraisal guidance
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]	Technology appraisal guidance
Oveporexton for treating type 1 narcolepsy [ID6622]	Technology appraisal guidance
Pain management (young people and adults)	Quality standard
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]	Technology appraisal guidance
Pancreatitis (including acute pancreatitis)	Quality standard
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]	Technology appraisal guidance
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]	Technology appraisal guidance
Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]	Technology appraisal guidance
Pelvic floor dysfunction	Quality standard
Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]	Technology appraisal guidance
Pembrolizumab for treating advanced or recurrent endometrial cancer with mismatch repair deficiency [ID6710]	Technology appraisal guidance
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]	Technology appraisal guidance
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]	Technology appraisal guidance
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]	Technology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808]	Technology appraisal guidance
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]	Technology appraisal guidance
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]	Technology appraisal guidance
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810]	Technology appraisal guidance
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]	Technology appraisal guidance

Results per page

10
25
50
All